Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemigliptin + metformin
- Development stage
- Phase 4
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Gemigliptin + metformin** is an oral fixed-dose antidiabetic combination, marketed as **Zemimet SR** and as **Zemiduo SR** in Mexico, for improving glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Gemigliptin is a selective, reversible dipeptidyl peptidase-4 inhibitor that prolongs endogenous incretin activity, while metformin is a biguanide that primarily reduces hepatic glucose production and improves insulin sensitivity. The combination was developed by LG Life Sciences, now LG Chem, and has demonstrated greater HbA1c reduction than either component alone in the 24-week phase III INICOM study. ([lgchem.com](https://www.lgchem.com/product-detail/zemimet-sr-tab?lang=en_US))
- Brand names
- Zemiduo SRZemimetZemimet SR
- Other names
- gemigliptin + metformin hydrochloridegemigliptin/metformingemigliptin/metformin hydrochloridegemigliptin/metformin sustained releasemetformin + gemigliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on gemigliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemigliptin + metformin.